Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients
about
Targeting the mTOR signaling network for cancer therapyAkt kinases in breast cancer and the results of adjuvant therapyIncreased level of phosphorylated akt measured by chemiluminescence-linked immunosorbent assay is a predictor of poor prognosis in primary breast cancer overexpressing ErbB-2.Celecoxib analogues disrupt Akt signaling, which is commonly activated in primary breast tumoursTreating breast cancer through novel inhibitors of the phosphatidylinositol 3'-kinase pathway.Akt expression and compartmentalization in prediction of clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumabReview on molecular and chemopreventive potential of nimbolide in cancerEverolimus plus exemestane for the treatment of advanced breast cancer: a review of subanalyses from BOLERO-2FoxO3a transcriptional regulation of Bim controls apoptosis in paclitaxel-treated breast cancer cell linesRegulation of mammary stem/progenitor cells by PTEN/Akt/beta-catenin signalingNitric oxide synthase and breast cancer: role of TIMP-1 in NO-mediated Akt activationActivation of SNAT1/SLC38A1 in human breast cancer: correlation with p-Akt overexpression.Neuregulin-1 regulates cell adhesion via an ErbB2/phosphoinositide-3 kinase/Akt-dependent pathway: potential implications for schizophrenia and cancer.Safety and pharmacokinetics of paclitaxel and the oral mTOR inhibitor everolimus in advanced solid tumours.Activation of Akt1 accelerates carcinogen-induced tumorigenesis in mammary gland of virgin and post-lactating transgenic miceComparison of Akt/mTOR signaling in primary breast tumors and matched distant metastasesThe PIK3CA gene as a mutated target for cancer therapy.Selective targeting of radiation-resistant tumor-initiating cells.Effectiveness and molecular interactions of the clinically active mTORC1 inhibitor everolimus in combination with tamoxifen or letrozole in vitro and in vivo.Integrative analyses of gene expression and DNA methylation profiles in breast cancer cell line models of tamoxifen-resistance indicate a potential role of cells with stem-like properties.Subcellular localization of activated AKT in estrogen receptor- and progesterone receptor-expressing breast cancers: potential clinical implicationsProfilin-1 overexpression upregulates PTEN and suppresses AKT activation in breast cancer cells.Potential prognostic value of heat-shock protein 90 in the presence of phosphatidylinositol-3-kinase overexpression or loss of PTEN, in invasive breast cancers.Phosphorylation status of Akt and caspase-9 in gastric and colorectal carcinomas.Alcohol consumption promotes mammary tumor growth and insulin sensitivity.FOXO1A is a target for HER2-overexpressing breast tumors.Expression of the Androgen Receptor, pAkt, and pPTEN in Breast Cancer and Their Potential in Prognostication.Boswellia sacra essential oil induces tumor cell-specific apoptosis and suppresses tumor aggressiveness in cultured human breast cancer cells.Akt activation is a common event in pediatric malignant gliomas and a potential adverse prognostic marker: a report from the Children's Oncology Group.Withania somnifera water extract as a potential candidate for differentiation based therapy of human neuroblastomasTargeted apoptotic effects of thymoquinone and tamoxifen on XIAP mediated Akt regulation in breast cancerParallel analysis of transcript and translation profiles: identification of metastasis-related signal pathways differentially regulated by drug and genetic modifications.Knockdown of Pdcd4 results in induction of proprotein convertase 1/3 and potent secretion of chromogranin A and secretogranin II in a neuroendocrine cell line.The prognostic value of phosphorylated Akt in breast cancer: a systematic review.Akt phosphorylation on Thr308 but not on Ser473 correlates with Akt protein kinase activity in human non-small cell lung cancerPI3K pathway mutations and PTEN levels in primary and metastatic breast cancer.mTORC1/C2 and pan-HDAC inhibitors synergistically impair breast cancer growth by convergent AKT and polysome inhibiting mechanisms.The prognostic value of phosphorylated AKT expression in non-small cell lung cancer: a meta-analysis.Akt activation and localisation correlate with tumour invasion and oncogene expression in thyroid cancer.Activation of the mTOR pathway by low levels of xenoestrogens in breast epithelial cells from high-risk women.
P2860
Q24658334-20082350-22D5-435C-89E4-4A12E69D8FDDQ24795435-112F7D34-E816-4A34-9AB0-5D6B247F6F97Q24810517-F71A9DE8-CBEA-4F3E-8EF0-4D3C9DC46D35Q24813725-CADE824F-B143-4427-95F0-D0525458FFE1Q24813788-FB4DFFD2-09A3-4E35-AA28-772EE0A653B6Q27851864-3406F2CC-98B3-42DE-9FA3-EA7EC727D83AQ28082973-35F62F33-7400-468D-8A54-DB1D5CEB74F1Q28085004-95CA914C-3675-48AF-95D0-6572705EB2E0Q28207468-2594B181-C10F-4C03-A935-8D554F35F3C9Q28475546-F23BF44D-2710-436F-80E4-792A494826E3Q28483470-3D4A5DD4-CA26-4F76-A65E-42840D7624ECQ31123096-0A64FC0F-623A-4E67-B604-63A665A8EF0BQ33312390-F8DADAFC-323E-4096-BC74-9E3CC9E2CF92Q33382682-E8400BAF-74AD-4734-A330-7BD59B22FB90Q33612060-6F2DAEFA-78E3-42AA-B8C4-E9281E35B3D2Q33640816-0A0DDC91-FE85-4033-8687-D9645D928651Q33699378-97E6ADB3-5DFA-4381-BF5A-3DBC46B70445Q33734733-9F1822F7-0068-48EE-A3A0-5F4BCDCB984DQ33739267-212879FE-CBAA-4F1D-BE5D-6714C696160DQ33754852-C9306FC0-4384-42C0-930D-EA217EE66C77Q33816285-130D271A-9974-4286-B69C-30564374BB88Q33867802-94B2E530-D8E5-43F8-9893-B691332D7B5EQ33889501-51458049-F129-43EC-8F22-7B4BD8D44070Q33898789-B4224EDC-4BBB-41B9-A9EE-7EB441C9258FQ33905831-30A0D466-BB53-4EAE-B886-7A1A82145631Q33959090-AC2A2A80-68CF-4E74-9FBC-90EE09D86F5FQ34092016-AAA26DB5-E2E0-4B30-B636-80AE74783B80Q34101905-3A217F17-820B-433E-A967-CAF4D6140579Q34196216-83762000-1EAB-4F28-835C-26B150B8FDE5Q34576380-E1B09EE1-A3FF-4C47-94B9-EF11FF6CE729Q34684291-8929A582-C58E-41F8-B655-FB565BD64414Q34768155-0095E44C-C24E-46AF-B9FE-BA52A0DEAFF7Q34786163-C15A6632-C3A1-416B-8D94-0582DF2134FDQ34925401-7F615349-C9C5-492C-9457-A31B98956932Q35034550-DA1EE008-86F4-4A64-A734-0FC42B19C9F3Q35038068-1371F6AE-D51C-4A56-850E-617850F76D78Q35053837-A308957F-0C17-4B20-91B7-DFE5F4BED568Q35069595-1CBC0801-74F9-4569-92E6-3B208654A248Q35445077-46DBBBA0-0C80-442C-A230-069A7AAB5B0AQ35479067-825D8532-AC27-43F2-8AFA-F9A3C1658359
P2860
Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
2002年论文
@zh
2002年论文
@zh-cn
name
Activation of AKT/PKB in breas ...... ong endocrine treated patients
@ast
Activation of AKT/PKB in breas ...... ong endocrine treated patients
@en
type
label
Activation of AKT/PKB in breas ...... ong endocrine treated patients
@ast
Activation of AKT/PKB in breas ...... ong endocrine treated patients
@en
prefLabel
Activation of AKT/PKB in breas ...... ong endocrine treated patients
@ast
Activation of AKT/PKB in breas ...... ong endocrine treated patients
@en
P2093
P2860
P356
P1476
Activation of AKT/PKB in breas ...... ong endocrine treated patients
@en
P2093
G Pérez-Tenorio
Southeast Sweden Breast Cancer Group
P2860
P2888
P304
P356
10.1038/SJ.BJC.6600126
P407
P577
2002-02-01T00:00:00Z